AMAT
60
3
AAL
32
-4
MTCH
50
2
AXP
74
-3
NEM
61
-2
OKE
71
-3
RHI
29
-4
SRE
52
2
AON
23
-9
PH
77
3
FOX
33
-6
KR
64
8
HD
31
5
PRU
47
-3
PGR
70
-3
BMY
35
2
BRK.B
47
-3
DTE
40
-2
FLS
55
3
JCI
49
2
AMAT
60
3
AAL
32
-4
MTCH
50
2
AXP
74
-3
NEM
61
-2
OKE
71
-3
RHI
29
-4
SRE
52
2
AON
23
-9
PH
77
3
FOX
33
-6
KR
64
8
HD
31
5
PRU
47
-3
PGR
70
-3
BMY
35
2
BRK.B
47
-3
DTE
40
-2
FLS
55
3
JCI
49
2
Financhill
Back

Oncternal Therapeutics 10K Form

Sell
37

ONCT
Oncternal Therapeutics

Last Price:
8.39
Seasonality Move:
0.33%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ONCT News And Ratings

See the #1 stock for the next 7 days that we like better than ONCT

ONCT Financial Statistics

Sales & Book Value

Annual Sales: $4.32M
Cash Flow: $-6.42M
Price / Cash Flow: 0
Annual Sales: $10.19
Price / Book: 0.82

Profitability

EPS (TTM): -13.43000
Net Income (TTM): $-39.48M
Gross Margin: $13.44M
Return on Equity: 0%
Return on Assets: 0%

Oncternal Therapeutics Earnings Forecast

Key Oncternal Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 9 years for ONCT is 91.24%.
  • The Selling, General & Administrative Expenses for ONCT have been equal to 268.40% of Gross Profit Margin.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 25 years have been positive in 14 years.

Oncternal Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ONCT
CUSIP: 68236P
Website: oncternal.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ONCT Technical Analysis vs Fundamental Analysis

Sell
37
Oncternal Therapeutics (ONCT) is a Sell

Is Oncternal Therapeutics a Buy or a Sell?